Anti-GD2 Recombinant Antibody (Dinutuximab) (CAT#: TAB-731)

Recombinant chimeric (human/Mouse) antibody expressed in CHO binding to human GD2. Dinutuximab is a chimeric monoclonal antibody that induces antibody dependent cell-mediated cytotoxicity. Dinutuximab is intended as maintenance therapy (targeting minimal residual disease) for high risk neuroblastoma, administered after induction therapy, autologous stem cell transplantation and/or radiotherapy.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Datasheet
  • MSDS
  • COA

Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Chimeric (Human/Mouse)
  • Type
  • IgG1 - kappa
  • Species Reactivity
  • Human
  • Applications
  • Suitable for use in ELISA, FC, IP, FuncS, IF, Neut, ICC and most other immunological methods.
  • Trade name
  • Unituxin
  • Generic Name
  • dinutuximab
  • Related Disease
  • Neuroblastoma

Product Property

  • Purity
  • >95.0% as determined by analysis by SDS-PAGE.
  • Storage
  • Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.

Target

  • Alternative Names
  • dinutuximab;Unituxin;Ch14.18;APN311;Disialoganglioside GD2;Ganglioside G2;GD2

Related Resources

  • Biosimilar Overview
Please refer to Dinutuximab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Dinutuximab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Dinutuximab"

Afuco™ Anti-GD2 ADCC Recombinant Antibody (Dinutuximab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant chimeric (human/Mouse) antibody expressed in CHO binding to human GD2. Dinutuximab is a chimeric monoclonal antibody that induces antibody dependent cell-mediated cytotoxicity. Dinutuximab is intended as maintenance therapy (targeting minimal residual disease) for high risk neuroblastoma, administered after induction therapy, autologous stem cell transplantation and/or radiotherapy.

See other products for "GD2"

Single-domain Antibody

CAT Product Name Application Type
NAB-770-sdAb Recombinant Anti-Human GD2 VHH Single Domain Antibody Neut, ChiP, IP, FUNC Llama VHH

Immunotoxin

CAT Product Name Application Type
AGTO-L018R anti-GD2 immunotoxin 14G2a (IgG)-RTA Cytotoxicity assay, Functional assay

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-731 Afuco™ Anti-GD2 ADCC Recombinant Antibody (Dinutuximab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody

Submit a review or a question
There are currently no Customer reviews or questions for TAB-731. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare